Latest Headlines

  1. Axcynsis Therapeutics Receives FDA Clearance For IND Application Of AT03-65, A Differentiated CLDN6-Targeting ADC, Powered By AxcynDOT™ Technology 1/15/2025

    Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly announces the clearance of its Investigational New Drug application (IND) by the United States Food and Drug Administration (FDA) of AT03-65 for the treatment of patients with CLDN-6 positive solid tumors.

  2. Enhanc3D Genomics Launches Suite Of 3D Multi-Omics Solutions To Accelerate Drug Development 1/14/2025

    Enhanc3D Genomics (‘Enhanced’ or ‘the Company’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug discovery.

  3. InveniAI Announces Launch Of AlphaMeld Corporation And Major Milestone Updates To Reflect Cutting-Edge Innovation In AI-Driven Drug Discovery 1/13/2025

    InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and development, today announced several transformative milestones as part of its continued commitment to revolutionizing the drug development process. 

  4. Rise Therapeutics Receives FDA IND Clearance To Initiate Clinical Testing Of R-5780 In Cancer 1/13/2025

    Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a cancer Phase 1 clinical trial for its program candidate, R-5780.

  5. Illumina And NVIDIA Collaborate To Decode Biology And Propel Precision Health 1/13/2025

    Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery.

  6. Every Cure Expands Collaboration With Google Cloud To Transform AI-Driven Drug Repurposing 1/13/2025

    Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today announced an expanded collaboration with Google Cloud to advance AI-driven drug repurposing.

  7. New Drug Hope For Prostate Cancer Patients 1/10/2025

    Prostate cancer that has become resistant to hormone therapy could be treated using a new drug that is currently in clinical trials for ovarian and bile duct cancer, according to research published in the journal Clinical Cancer Research.

  8. Iktos And Cube Biotech Announce Launch Of Small Molecule AI Drug Discovery Collaboration 1/10/2025

    Iktos, a leader in Artificial Intelligence (AI) and Robotics for drug design, and Cube Biotech, a pioneer in membrane protein production and purification technologies, today announced a strategic collaboration to discover novel small molecule agonists of the Amylin Receptor.

  9. Kardigan Launches With Industry-Leading Team To Modernize Cardiovascular Drug Development With Late-Stage Portfolio Of Personalized Medicines 1/10/2025

    Kardigan, a heart health company modernizing cardiovascular drug development, launched today with a mission to develop multiple targeted treatments in parallel, bringing people with cardiovascular diseases closer to the cures they deserve.

  10. Zai Lab Announces Strategic Partnership With MediLink Therapeutics To Develop A Novel LRRC15 Antibody-Drug Conjugate 1/9/2025

    Zai Lab Limited today announced a new strategic collaboration and worldwide license agreement with MediLink Therapeutics (Suzhou) Co., Ltd. (“MediLink”) to use MediLink’s TMALIN antibody-drug conjugate (ADC) platform for the development of a novel LRRC15 ADC, ZL-6201, consisting of an antibody discovered by Zai Lab.